Drugs / Siremadlin
Siremadlin
also known as
HDM201 · HDM-201 SUCCINATE · HDM201 BBA · NVP-HDM 201 · NVP-HDM201-BBA · SIREMADLIN SUCCINATE · Siremadlina · Siremadline
Small molecule targets MDM2 via inhibition
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05599932 | Dec 2022 → Sep 2023 | liver disease, severe congenital | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05155709 | May 2022 → Apr 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04496999 | Jul 2020 → Sep 2022 | acute myeloid leukemia | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 1 | NCT03940352 | Jun 2019 → Aug 2024 | acute myeloid leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03714958 | Dec 2018 → Sep 2023 | colorectal cancer, metastatic malignant neoplasm | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1 | NCT02890069 | Oct 2016 → Feb 2022 | colorectal cancer, non-small cell lung carcinoma, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02601378 | Feb 2016 → Jan 2022 | uveal melanoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02343172 | Mar 2015 → Oct 2019 | liposarcoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02143635 | Jul 2014 → Jun 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05447663 | Feb → Oct 2023 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT05180695 | Apr 2022 → Feb 2027 expected | soft tissue sarcoma | Centre Leon Berard | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03760445 | Nov 2019 → Jul 2021 | acute myeloid leukemia | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04097821 | Sep 2019 → May 2023 | myelofibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04116541 | Jan 2020 → Oct 2026 expected | cancer | Centre Leon Berard | Recruiting | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Siremadlin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447663 ↗ |
| Known as | HDM-201 SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | HDM201 | “escalating doses of HDM201: 60 mg (starting dose); 80 mg; 100 mg; 120 mg” NCT05180695 ↗ |
| Known as | HDM201 BBA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | NVP-HDM 201 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | NVP-HDM201-BBA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | SIREMADLIN SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | Siremadlina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Known as | Siremadline | ChEMBL registry synonym — accepted as the source's own label CHEMBL3653256 ↗ |
| Action | Inhibit | “HDM201: Therapeutic class HDM2 inhibitor” NCT03714958 ↗ |
| Modality | Small molecule | — CHEMBL3653256 ↗ |
| Route | Oral | “Oral HDM201” NCT02343172 ↗ |
| Target | HDM2 | “HDM201: Therapeutic class HDM2 inhibitor” NCT03714958 ↗ |